Overcoming Barriers to the Early Recognition and Diagnosis of Rheumatoid Arthritis in Real-World Practice: Strategies to Expedite Treatment to Remission

Release Date: January 25, 2017
Expiration Date: January 25, 2018
Expected time to completion: 1.0 hour(s)


Brian Mandell, MD, PhD, FACR, MACP
Professor and Chairman of Academic Medicine
Department of Rheumatology
Editor in Chief
Cleveland Clinic Journal of Medicine
Cleveland Clinic
Cleveland, Ohio

Program Overview

Rheumatoid arthritis (RA) is a chronic, painful, debilitating disease that affects activities of daily living in many patients. It imposes a significant healthcare burden in the US and most patients with RA continue to report poor quality of life despite treatment. Although many therapies and guidance for their use are currently available to treat RA, many deficits in the knowledge as well as compliance of healthcare providers with published guidelines have been reported. New clinical practice guidelines are available and newer therapies that target the immune system are emerging. These advances are expected to address some of the unmet medical needs of patients with RA and challenges in current practice.

In today’s practice, several clinical practice gaps limit effective care including delayed diagnosis, inadequate early treatment to remission, and lack of communication with patients to improve shared decision-making for treatment and follow-up care. Continuing education that improves physician awareness of these gaps and offers strategies to address them may improve patient outcomes in RA, leading to more accurate screening and diagnosis and expedited treatment to remission.

Target Audience

This educational activity has been designed for primary care physicians involved in the management of patients with RA.


Upon completion of this educational activity, participants should be able to:

• Heighten awareness to improve the early diagnosis of RA
• Apply guideline recommendations for treating to remission and preserving patient function in RA
• Review the underlying pathophysiology of RA and the role of emerging targeted therapies, including cytokine inhibition, for patients with RA
• Describe an integrated approach to RA patient care that includes a multidisciplinary healthcare team and patient education to improve shared decision-making

Directions to Learner

There are no fees for participating and receiving CME credit for this activity. During the period of January 25, 2017 through January 25, 2018, participants must:

• Read the learning objectives and faculty disclosure
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.


Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Brian Mandell, MD, PhD, FACR, MACP
Consultant: AstraZeneca, Horizon Pharma, Ironwood Pharmaceuticals Research Grants: Horizon Pharma

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals, do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Privacy Policy

When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)

Minimum System Requirements

Windows XP, Windows 2000, Windows Vista, and Windows 7 Intel Pentium 4, 2.33 + GHz (or equivalent)
Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer is not recommended.

Mac OS X v10.4 or later
1.8GHz or faster (or equivalent)
Intel Core Duo 1.33GHz or faster (or equivalent)
Adobe® Flash® Player 10

Click here for more information on minimum system requirements.


The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

begin pretest



Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals.